How Should Clinical Evaluation Documentation Be Prepared Under EU MDR?

Short answer: Under EU MDR 2017/745, clinical evaluation is a core requirement for demonstrating a device's safety and performance. Prepare a Clinical Evaluation Plan (CEP; sometimes referred to as a CER Plan), conduct a systematic literature search using the PICO framework across at least two databases, appraise and extract data, provide an equivalence justification if equivalence is claimed, analyze clinical data, update the Clinical Evaluation Report (CER) with PMS and PMCF inputs, and submit the clinical evaluation as part of the technical documentation for Notified Body review.

EU MDR Clinical Evaluation Documentation: How to Prepare?

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

This FAQ addresses priority questions that manufacturers need to assess in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance. It focuses on practical decisions in real projects.

Content Structure

• Executive Summary
• Applicable Scenarios and Core Questions
• Regulatory Decision Logic
• Core Documentation and Evidence
• Common Errors
• Manufacturer Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-Up Questions
• Further Reading
• Scope of Application

Executive Summary

Under the EU Medical Device Regulation (MDR 2017/745), clinical evaluation is a core element in demonstrating device safety and performance. Preparation should follow MEDDEV 2.7/1 Rev.4 and MDCG guidance.

First, prepare a Clinical Evaluation Plan (CEP; sometimes referred to as a CER Plan). It should specify the device description, intended purpose, clinical background, equivalence justification (if applicable), evaluation methods (literature search, clinical investigation, or both), and data acceptance criteria.

Second, conduct the literature search. Use the PICO framework to build the search strategy, cover at least two databases (e.g., PubMed and Cochrane), screen the search results, assess risk of bias (e.g., using the CASP tool), and extract data. If equivalence is claimed, provide an equivalence justification report demonstrating that the device is substantially equivalent to the equivalent device in technical, biological, and clinical characteristics.

Then analyze the clinical data, evaluate adverse event rates and performance indicators, and update the Clinical Evaluation Report (CER). The CER must include post-market surveillance (PMS) data inputs, such as a PMCF plan or report.

Finally, submit the clinical evaluation as part of the technical documentation to the Notified Body for review. Note: for Class III or implantable devices, a post-market clinical follow-up (PMCF) plan or a summary of existing clinical investigations is also required.

Compiled based on AIMEILI registration practice references, medical device international registration resources, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Questions

Manufacturers are most concerned with three points: first, how to meet the MDR's strict clinical evidence requirements and avoid rejection due to insufficient data; second, how to complete a literature search or clinical investigation efficiently within a limited budget; and third, how to leverage existing CE certificates (such as under MDD) for MDR compliance. In addition, the difficulty of equivalence justification and the design of PMCF activities are common pain points.

Regulatory Decision Logic

First, determine the clinical evaluation route based on device classification (Class IIa, IIb, III, or implantable). If sufficient clinical data exist for an equivalent device, the equivalence route may be used; otherwise, a clinical investigation is needed. Key decision points include: are applicable standards relevant (e.g., ISO 14155)? Is post-market clinical follow-up (PMCF) mandatory? For Class III or implantable devices, a PMCF plan must be provided. Notified Bodies focus on non-inferiority endpoints and adverse event rates.

Core Documentation and Evidence

• Clinical Evaluation Plan (CEP)
• Literature search report (including search strategy, screening flow diagram, and literature list)
• Risk-of-bias assessment forms (e.g., CASP or Cochrane RoB tools)
• Data extraction forms and summary tables (e.g., effectiveness and safety results)
• Equivalence justification report (if applicable, comparing technical, biological, and clinical characteristics)
• Latest version of the Clinical Evaluation Report (CER)
• Post-Market Surveillance (PMS) Plan and PMCF plan/report

Common Errors

• Insufficient literature search scope: using only a single database or not using the PICO framework.
• Inadequate equivalence justification: failure to provide comparative data on key parameters such as chemical composition and design principles.
• Ignoring negative data: reporting only positive results and failing to analyze adverse events or failures.
• Disconnect between CER and PMS: the CER does not cite PMS data, or the PMCF plan does not correspond to CER conclusions.
• Lack of statistical review: clinical data are not statistically analyzed, and sample size rationale is not explained.

Manufacturer Preparation Checklist

• Form a cross-functional team (regulatory, medical, R&D, clinical).
• Purchase or subscribe to literature database access.
• Allocate resources for literature search and risk-of-bias assessment training.
• Establish document templates (CER, search report, equivalence justification).
• Plan PMCF in advance: design an observational study or RCT protocol.
• Communicate with the Notified Body in advance: confirm acceptable data criteria.
• Allow review buffer time: the CER review cycle is usually 6-12 months.

AIMEILI Perspective

The core of MDR clinical evaluation is data relevance and sufficiency. We recommend that manufacturers start the literature search early and build a dynamic PMS database. For high-risk devices, even if equivalent device data exist, a small post-market study is strongly recommended. Do not rely on an old MDD-era CER; MDR requires stricter bias analysis and data transparency. In addition, outsourcing to an experienced contract research organization (CRO) can reduce costs, but internal staff must remain deeply involved in the logic and rationale.

Frequently Asked Follow-Up Questions

Can manufacturers rely entirely on literature data without conducting a clinical investigation?

Answer: This is only applicable to Class IIa and some Class IIb devices, and it requires demonstrating high equivalence with an equivalent device. However, Notified Bodies generally require at least one clinical investigation for implantable or Class III devices.

Must PMCF include randomized controlled trials?

Answer: Not necessarily. Depending on risk, observational studies, registry studies, or clinical follow-up may be used. However, sample size and follow-up duration must be clearly defined.

Further Reading

• Previous: What are the cybersecurity registration requirements for medical devices under US FDA?
• Next: How long does the medical device registration process take under Malaysia MDA?
• Recommended: What should manufacturers prepare before medical device registration in Australia TGA?
• Recommended: Can CE documentation be reused for medical device registration with Singapore HSA?
• Recommended: What core documentation is required for medical device registration with UAE MOHAP?
• Recommended: Why is the medical device registration cycle so long with Brazil ANVISA?
• Recommended: What is the difference between a medical device import license and a registration certificate in Vietnam?
• Recommended: How should manufacturers choose a local authorized representative for medical device registration in Indonesia?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Scope of Application

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as supplementary judgment.

Scope: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal opinions.